NZ708511A - Methods for controlling blood pressure and reducing dyspnea in heart failure - Google Patents

Methods for controlling blood pressure and reducing dyspnea in heart failure

Info

Publication number
NZ708511A
NZ708511A NZ708511A NZ70851113A NZ708511A NZ 708511 A NZ708511 A NZ 708511A NZ 708511 A NZ708511 A NZ 708511A NZ 70851113 A NZ70851113 A NZ 70851113A NZ 708511 A NZ708511 A NZ 708511A
Authority
NZ
New Zealand
Prior art keywords
blood pressure
methods
heart failure
controlling blood
dyspnea
Prior art date
Application number
NZ708511A
Other languages
English (en)
Inventor
Edward Spindler
Loretta Itri
Gregory Williams
Ming-Yi Hu
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of NZ708511A publication Critical patent/NZ708511A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ708511A 2012-10-26 2013-10-26 Methods for controlling blood pressure and reducing dyspnea in heart failure NZ708511A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261719127P 2012-10-26 2012-10-26
PCT/US2013/066990 WO2014066870A1 (en) 2012-10-26 2013-10-26 Methods for controlling blood pressure and reducing dyspnea in heart failure

Publications (1)

Publication Number Publication Date
NZ708511A true NZ708511A (en) 2018-11-30

Family

ID=50545374

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ708511A NZ708511A (en) 2012-10-26 2013-10-26 Methods for controlling blood pressure and reducing dyspnea in heart failure

Country Status (18)

Country Link
US (1) US10881645B2 (enExample)
EP (1) EP2925128B1 (enExample)
JP (2) JP6329957B2 (enExample)
KR (1) KR102299073B1 (enExample)
CN (2) CN110840890A (enExample)
AU (1) AU2013334081B2 (enExample)
BR (1) BR112015009291B1 (enExample)
CA (1) CA2889584C (enExample)
EA (1) EA030354B1 (enExample)
ES (1) ES2671639T3 (enExample)
IL (1) IL238462A0 (enExample)
MX (1) MX359768B (enExample)
NZ (1) NZ708511A (enExample)
PL (1) PL2925128T3 (enExample)
TR (1) TR201807636T4 (enExample)
UA (1) UA117571C2 (enExample)
WO (1) WO2014066870A1 (enExample)
ZA (1) ZA201503741B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2950154T3 (es) * 2014-05-19 2023-10-05 Chiesi Farm Spa Nanopartículas de clevidipino y composiciones farmacéuticas de las mismas
BR112021017009A2 (pt) * 2019-03-05 2021-11-09 Windtree Therapeutics Inc Formulação intravenosa contendo istaroxima para o tratamento da insuficiência cardíaca aguda (ahf)
CN114966056B (zh) * 2022-06-08 2024-07-02 四川大学华西医院 筛查急性主动脉夹层的试剂盒和系统

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9303657D0 (sv) 1993-11-05 1993-11-05 Astra Ab Short-acting dihydropyridines
SE9303744D0 (sv) 1993-11-12 1993-11-12 Astra Ab Pharmaceutical emulsion
SE9804002D0 (sv) 1998-11-23 1998-11-23 Astra Ab New manufacturing process
AR071810A1 (es) * 2008-05-16 2010-07-14 Corthera Inc Metodo de tratamiento de la disnea asociada con la insuficiencia cardiaca aguda. relaxina h2. uso.
EP2320740B1 (en) 2008-08-01 2014-03-26 The Medicines Company Pharmaceutical compositions of clevidipine and methods for producing low impurity concentrations of the same
EP2320739B1 (en) 2008-08-01 2019-11-27 Chiesi Farmaceutici S.p.A. Pharmaceutical compositions and methods for stabilizing the same
HRP20200445T1 (hr) * 2009-11-11 2020-06-12 Chiesi Farmaceutici S.P.A. Metode liječenja ili prevencije tromboze u stentu
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
DK2627173T4 (en) * 2010-10-12 2018-10-22 Chiesi Farm Spa CLEVIDIPINE EMULSUM FORMULATIONS CONTAINING ANTIMICROBIANTS
RU2623039C2 (ru) 2011-04-01 2017-06-21 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Дигидропиридины (клевидипин) кратковременного действия для применения в восстановлении после инсульта

Also Published As

Publication number Publication date
AU2013334081A1 (en) 2015-06-11
ES2671639T3 (es) 2018-06-07
MX359768B (es) 2018-10-10
MX2015005341A (es) 2016-05-24
CN104968199A (zh) 2015-10-07
EA030354B1 (ru) 2018-07-31
TR201807636T4 (tr) 2018-06-21
EA201590825A1 (ru) 2015-09-30
KR20150104084A (ko) 2015-09-14
JP2018065875A (ja) 2018-04-26
IL238462A0 (en) 2015-06-30
EP2925128B1 (en) 2018-04-11
US20140121247A1 (en) 2014-05-01
ZA201503741B (en) 2022-09-28
BR112015009291B1 (pt) 2021-03-16
JP6329957B2 (ja) 2018-05-23
JP2015535258A (ja) 2015-12-10
AU2013334081B2 (en) 2017-05-18
CN110840890A (zh) 2020-02-28
PL2925128T3 (pl) 2018-10-31
US10881645B2 (en) 2021-01-05
EP2925128A4 (en) 2016-06-08
EP2925128A1 (en) 2015-10-07
BR112015009291A2 (pt) 2017-07-04
WO2014066870A1 (en) 2014-05-01
UA117571C2 (uk) 2018-08-27
CA2889584C (en) 2018-08-14
KR102299073B1 (ko) 2021-09-09
CA2889584A1 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
EP4233861A3 (en) Compositions for treatment of essential tremor
MX362626B (es) Métodos para tratar pacientes pediátricos usando dexmedetomidina..
TN2011000217A1 (en) Pirfenidone treatment for patients with atypical liver fuction
NZ714963A (en) Compositions and methods for treating anemia
MX2022004012A (es) Solucion de bloqueo de cateter y terapia de bloqueo de cateter.
HK1198869A1 (en) Combination treatments for hepatitis c
PH12016501357A1 (en) Pharmaceutical preparation containing pyridylamino acetic acid compound
NZ592615A (en) Method for treating or preventing thrombosis using 150 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
UA105191C2 (ru) Лечение пирфенидоном пациентов с атипической функцией печени
JP2017501154A5 (enExample)
PH12015502465A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
HK1255584A1 (zh) 使用阿坎酸及d-环丝胺酸的联合疗法
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
WO2010107251A3 (ko) 파카스트리사민을 유효성분으로 함유하는 과증식성 피부질환과 악성흑생종의 예방 또는 치료용 약학적 조성물
NZ708511A (en) Methods for controlling blood pressure and reducing dyspnea in heart failure
MY179794A (en) Compound composition for inhalation used for treating asthma
NZ592613A (en) Method for treating or preventing thrombosis using >150 mg to 300 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
NZ751972A (en) Treatment of prurigo nodularis
WO2013058627A3 (ko) 레바미피드를 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물
Morales Bradycardia and hypotension: case report
JO3645B1 (ar) أشكال جرعة دوائية تحتوي صوديوم 1-[6-(مورفولين-4- يل) بيريميدين-4- يل]-4-(1h-3،2،1- ترايازول-1- يل)-1h- بيرازول-5- ولات
HK1225969A1 (zh) 利用低剂量的拉喹莫德治疗克隆氏病
ZA202102392B (en) Medicament for therapeutic treatment and/or improvement of sepsis accompanied by coagulopathy
CN106491731A (zh) 治疗肝硬化的中药
NZ600486A (en) Pirfenidone treatment for patients with atypical liver function

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: CHIESI FARMACEUTICI S.P.A., IT

Effective date: 20161215

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2020 BY COMPUTER PACKAGES INC

Effective date: 20191001

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2021 BY COMPUTER PACKAGES INC

Effective date: 20201001

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2022 BY COMPUTER PACKAGES INC

Effective date: 20210930

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2023 BY COMPUTER PACKAGES INC

Effective date: 20220930

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2024 BY COMPUTER PACKAGES INC

Effective date: 20230930

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2025 BY COMPUTER PACKAGES INC

Effective date: 20240930

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2026 BY COMPUTER PACKAGES INC

Effective date: 20250930